Background
Infliximab is a monoclonal anti-tumor necrosis factor alpha (TNFα) antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ankylosing spondylitis. Infliximab is a TNFα blocker and a chimeric human/mouse monoclonal IgG1 antibody.
Product Details
| Reactivity | Human |
| Specificity | Detects human TNFα in direct ELISA. This non-therapeutic antibody uses the same variable region sequences (VH, VL) as the therapeutic antibody Infliximab. This product is for research use only. |
| Source | Recombinant Monoclonal Human IgG1 Clone #FB016 |
| Purification | Protein A/G purified from CHO cell culture supernatant |
| Immunogen | Human TNFα |
| Endotoxin Level | <0.10 EU per 1 µg of the antibody by the LAL method |
| Formulation | 0.2 µm filtered solution in PBS |
| Applications | • Flow Cytometry: 0.25 µg/106 cells • Neutralization: Measured by its ability to neutralize TNFα-induced cytotoxicity in the L‑929 mouse fibroblast cell line. The neutralization dose is typically 2-12 ng/mL in the presence of 0.25 ng/mL Recombinant Human TNFα and actinomycin D. |
| Reconstitution | Reconstitute at 0.5 mg/ml in sterile 1xPBS |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at -20 to -70°C |
| Storage Conditions | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. • 12 months from the date of receipt at -20 to -70°C as supplied. • 1 month at 2 to 8°C under sterile conditions |